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A new antibacterial coating made of poly(L-lysine)/hyaluronic acid (PLL/HA) multilayer films and liposome aggregates
loaded with silver ions was designed. Liposomes filled with an AgNO3 solution were first aggregated by the addition
of PLL in solution. The obtained micrometer-sized aggregates were then deposited on a PLL/HA multilayer film,
playing the role of a spacer with the support. Finally, HA/PLL/HA capping layers were deposited on top of the
architecture to form a composite AgNO3 coating. Release of encapsulated AgNO3 from this composite coating was
followed and triggered upon temperature increase over the transition temperature of vesicles, found to be equal to
34 °C. After determination of the minimal inhibitory concentration (MIC) of AgNO3 in solution, the antibacterial
activity of the AgNO3 coating was investigated against Escherichia coli. A 4-log reduction in the number of viable
E. coli cells was observed after contact for 120 min with a 120 ng/cm2 AgNO3 coating. In comparison, no bactericidal
activity was found for PLL/HA films previously dipped in an AgNO3 solution and for PLL/HA films with liposome
aggregates containing no AgNO3 solution. The strong bactericidal effect could be linked to the diffusion of silver ions
out of the AgNO3 coating, leading to an important bactericidal concentration close to the membrane of the bacteria.
A simple method to prepare antibacterial coatings loaded with a high and controlled amount of AgNO3 is therefore
proposed. This procedure is far superior to that soaking AgNO3 or Ag nanoparticles into a coating. In principle, other
small bactericidal chemicals like antibiotics could be encapsulated by this method. This study opens a new route to
modify surfaces with small solutes that are not permeating phospholipid membranes below the phase transition
temperature.
Introduction
Bacterial infections at the site of implanted medical devices
present a serious source of problems, leading, if untreated, to
chronic microbial infection, inflammation, tissue necrosis to
septicaemia and eventually to death.1,2 Such infectious diseases
can, for example, be due to Staphylococcus epidermidis and
Escherichia coli, in the case of intravascular catheter associated
infections,1,3 or Staphylococcus aureus, in the case of metallic
implants.4 In the long term, certain medical implants in the body
suffers from a progressive accumulation of proteins, bacteria,
and cells on their surface, developing a biofilm.5 Commonly in
postsurgery therapy, antibiotic treatments (delivered orally or by
injection) are used to avoid bacterial growth. However, new
antibacterial strategies are needed in the situation where more
and more bacteria are antibiotic-resistant.6,7 Surface treatments
have been developed to reduce bacterial adhesion by modifying
the physicochemical properties of the substrate in order to reduce
the interactions between bacteria and the substrate. These
“passive” coatings are based on polyethylene glycol (PEG)8-11
or hydrophilic polyurethane12,13 surface modification and render
the surface hydrophilic, allowing a limited bacterial adhesion
and proliferation. A recent alternative approach was proposed
based on “active” coatings by integrating antibacterial agents at
the implant site. The advantage of a direct delivery at the site
of implantation is the high local concentration that can be delivered
during the critical short-term postimplantation period (several
hours) without reaching the systemic toxicity level of the agent.
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Antibiotic-coated surfaces (penicillin or ciprofloxacin) are thus
proposed,7,14 but their effectiveness is limited. The inhibitory
and bactericidal properties of silver have been known for
centuries.15 Nontoxic to human cells, silver and silver ions can
act against a broad spectrum of bacterial strains. Silver is
commercially used in numerous products, including water
sterilization and therapeutic applications.16
Polyelectrolyte multilayer films, obtained by the alternate
deposition of cationic and anionic polymers, emerged as a simple
approach to functionalize surfaces in a controlled way.17,18 These
films grow either linearly,19,20 or exponentially.21-23 Such films
find a wide application in surface treatments,24,25 membranes,26,27
chemical or biological detections,28,29 biotechnology,30-32 and
biomaterials.33-35 In particular, this technique also allows
preparation of nanoarchitectures exhibiting specific properties
in the control of cell activation.36,37 Moreover, these multilayer
films can act as reservoirs for active molecules38 and are therefore
potentially suited for the development of local drug delivery
systems.39 An antiadhesive film was developed leading to a
reduction in adhesion by about 92% of E. coli cells compared
to bare substrate.8 LbL films with embedded antimicrobial
peptides,40 embedded hydrophobic bactericide,41 or films built
with chitosan, a polyelectrolyte used as an antibacterial agent,42,43
were investigated. LbL films with inserted silver nanoparticles
were also designed to induce an antibacterial effect.44-49
However, the main point is not the presence of metallic silver
on the catheter, but the ability of the silver to be dissociated into
silver ions.50,51 Silver ions, having antibacterial properties, are
not necessarily present at a surface coated with metallic silver.
Lok et al.52 showed that the antibacterial activities of silver
nanoparticles are dependent on chemisorbed Ag+ ions, formed
owing to extreme sensitivity to oxygen. Possible modes for the
release of chemisorbed Ag+ species may involve direct association
between the nanoparticles and the bacteria. In vivo studies of
silver coatings failed to demonstrate a decrease of bacterial
adhesion.53,54 Silver ions, having antibacterial properties, are
not actively released by these coatings and are not necessarily
present at a surface coated with metallic silver.
Liposomes are well-known and widely used in medical
applications55,56 due to their small size and the high integrity of
the lipid bilayer. They allow small amphiphilic molecules and
water soluble species to be kept and released.57 Thus, surfaces
with immobilized vesicles are perfect candidates for drug delivery
applications.58,59 Our recent studies were devoted to the buildup
of liposome-containing polyelectrolyte multilayer films,60-64 with
liposomes playing the role of reservoirs with controlled release.
However, the amount of immobilized active compound is low
due to the limited thickness of one layer of liposomes corre-
sponding to approximately 100 nm in thickness.65 Our recent
findings on complexation of vesicles with polyelectrolytes suggest
a way to overcome the low loading capacity of such films.66-71
With a fast injection of the vesicles into a PLL solution, obtained
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complexes can be changed from isolated polymer-coated vesicles
to vesicle aggregates, depending on the polymer/lipid ratio. PLL-
stabilized liposomes can be used as containers filled with active
compounds able to release them upon heating over the lipid
transition temperature. The same is true not only for single vesicles
but also for vesicle aggregates.
The main goal of this work was to obtain biocompatible surfaces
with an antibacterial activity by using the innovative approach
of surface functionalization. The controlled release of silver ions,
which can act against a wide range of bacteria, has been pursued
as an alternative strategy for reducing bacterial proliferation. To
this aim, surfaces were functionalized by AgNO3-containing
liposome aggregates (AgNO3-liposome aggregates) embedded
in PLL/HA multilayer films. The obtained architecture was named
AgNO3 coating. Liposome aggregates were used as silver ion
reservoirs for coating of solid surfaces. Release of silver ions
from the coating was investigated at room temperature and at
37 °C. The bactericidal effect of AgNO3 coatings was character-
ized.
Experimental Section
Materials. The used lipids, 1,2-dipalmitoyl-sn-glycero-3-phos-
phocholine (DPPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine
(DMPC), and 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glyc-
erol)] sodium salt (DPPG), were purchased from Avanti Polar Lipids.
Cholesterol (CL, ref C-8667), 4-(2-hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES, ref H3375), poly-L-lysine hydrobromide
with MW) 28 kDa (PLL, ref P7890), and Triton X-100 (ref 23,472-
9) were purchased from Sigma-Aldrich. Hyaluronic acid with MW
) 420 kDa (HA, ref 002570) and 5(6)-carboxyfluorescein (CF, ref
21877) were respectively purchased from Lifecore Biomedical and
Fluka. Silver nitrate (AgNO3), sodium iodide (NaI), and sodium
nitrate (NaNO3) were purchased from VWR Prolabo. Sephadex G-75
(G75120) was purchased from Sigma-Aldrich. All products except
PLL were used without further purification. Microscopy cover glasses
with a diameter of 12 or 30 mm were purchased from Marlenfeld
GmBH. Throughout this study, 10 mM HEPES buffer prepared at
pH 7.4 containing 150 mM NaNO3 was used and will be mentioned
in the text as HEPES. The water used in all experiments was prepared
in a three-stage Millipore Milli-Q Plus 185 purification system and
had a resistivity of 18.2 MΩ cm.
Purification of PLL. PLL used in this study contains bromide
ions that have to be removed in order to maintain the integrity of
AgNO3-liposomes, which could be destroyed by the formation of
insoluble AgBr in contact with PLL solution. Bromide counterions
were eliminated by a 10 M NaOH solution dropped in to 1 mL of
PLL solution (at a concentration of 13.5 mg/mL) to reach a
concentration of 1 M NaOH. At this concentration, all the amino
groups of PLL become neutral and then PLL precipitates. The formed
gel was centrifuged during 5 min at 10 000g and the supernatant
removed. After the addition of an identical volume of 1 M NaOH
solution, the gel was again centrifuged. This step was repeated four
times to remove completely bromide ions. Two milliliters of HEPES
buffer was finally added to the precipitate at the desired concentration.
The quasiquantitative removal of bromide counterions from the PLL
solution was checked by the absence of turbidity at the addition of
1 M AgNO3.
Preparation of CF- and AgNO3-Liposomes. Unilamellar
phospholipid vesicles filled with CF or AgNO3 solutions were
prepared by the ultrasonication method. Briefly, 2 mg of CL was
added to the lipid solution in chloroform containing 12 mg of DPPC,
4 mg of DMPC, and 2 mg of DPPG, with DPPG previously dissolved
in chloroform:methanol (1:1 v/v) solution. The ratio of the
components DPPC/DMPC/DPPG/CL was 60/20/10/10 w/w. The
final mixture (4-5 mL) was placed in 100 mL round-bottom flask.
The solvent was removed by rotary evaporation at 35 °C and intensive
rotation of 200 rpm under a pressure of 300 mbar during 20 min and
then overnight at 17 mbar at room temperature. The thin lipid film
was hydrated at 55 °C with 4 mL of 1 M AgNO3 solution at a desired
concentration in HEPES or a similar volume of 0.2 mg/mL CF in
HEPES solution. Then, the lipid suspension was transferred in a
glass tube and sonicated during 90 min (40 W, 50% impulse time)
by Vibra-Cell VC 600 (Sonics & Materials). The glass tube was put
in a water bath to maintain the temperature in the range of 50-65
°C. The temperature of the lipid suspension was measured from
time to time during the procedure. The titanium particles originating
from the sonicator tip were removed by centrifugation. One milliliter
of slightly turbid suspension of vesicles was subjected to a 1 × 20
cm2 glass column filled with Sephadex G-75 (gel volume 12 mL),
previously equilibrated with HEPES. The fraction of the collected
liposomes was stored at 4 °C.
Dynamic Light Scattering and Electrophoretic Mobility. The
average hydrodynamic diameter of the vesicles and their electro-
phoretic mobility were respectively determined by dynamic light
scattering (DLS) and laser Doppler electrophoresis. These experi-
ments were carried out at 25 °C using a Malvern Zetasizer 4 apparatus
(Malvern Instruments). The -potential was calculated from the
measured electrophoretic mobility using the Smolukovski equation.
CF- and AgNO3-containing liposomes are respectively denoted
CF-liposomes and AgNO3-liposomes.
PLL/HA Multilayer Films. The buildup of PLL/HA multilayer
films by the layer-by-layer technique consisted of sequential dipping
during 10 min in the polycation (PLL) and in the polyanion (HA)
solutions with intermediate washing steps with HEPES by means
of a dipping robot (Riegler & Kirstein GmbH). PLL samples were
previously purified from bromide ions as described above. Before
use, the polyelectrolyte solutions prepared at 0.5 mg/mL were filtrated
through a 0.22 µm filter. PLL/HA films were built on 12 mm glass
slides. Glass slides were cleaned by successive incubations at 60 °C
in 2% (w/v) Hellmanex (Hellma GmbH), 0.01 M sodium dodecyl
sulfate, and 0.1 M HCl during 15 min for each solution followed
by multiple rinsing with pure Milli-Q water. The obtained structure
is denoted (PLL/HA)20 for a film with 20 PLL/HA pairs of layers
and has a thickness of about 5 µm.72
Preparation of AgNO3 or CF Coatings. First AgNO3-liposome
aggregates were prepared by injecting 2 mL of AgNO3-liposome
solution into 2 mL of 0.1 mg/mL PLL solution. The formed
suspension was centrifuged during 2-3 min at 1000g, and the
supernatant was washed twice with HEPES to remove the excess
of PLL and finally resuspended in 300 µL of the same buffer to
obtain AgNO3-liposome aggregates. The concentration of liposomes
was chosen to have a final molar ratio of PLL amino groups/DPPG
equal to 2. THe AgNO3 coating was prepared as follows: 70 µL of
AgNO3-liposome aggregates was deposited on a (PLL/HA)20 film,
built on a glass slide, and dried 2 h under the laminar flow of a hood.
To tune the AgNO3 content of the coating, AgNO3-liposome
aggregate solution was diluted at a desired concentration and adsorbed
on the film. Additional HA/PLL/HA layers were deposited on the
architecture by alternating immersion of the glass slide in HA and
PLL solutions separated by rinsing steps. The total amount of AgNO3
in the formed coating was determined by gravimetric analysis of
silver ion release after film dissolution (see “Release of Silver Ions
from AgNO3 Coatings” in the Experimental Section). The final
architecture (PLL/HA)20-AgNO3-liposome aggregates-HA/PLL/
HA, called AgNO3 coating, was stored at 4 °C in HEPES solution.
In order to prepare CF coatings, the same protocol was used with
CF-liposomes.
Loading CF in CF Coatings. The loading of CF coatings was
achieved by using the liposomes filled with CF. To determine the
loading, the fluorescence intensity of the supernatant was measured
after the complete dissolution of the CF coating. For this procedure,
a first treatment was applied to obtain a complete removal of the
polyelectrolyte multilayer film after deprotonation of PLL: 200 µL
of a 0.05 M NaOH solution was deposited during 5 min on the CF
coating. Then, a treatment was applied to reach the decomposition
of the lipid bilayer: 1 mL of Tris buffer solution (0.5 M Tris, 0.25
M NaCl, pH 8.3) with 1% of Triton X100 was added to the supernatant
and the obtained mixture was heated to 75 °C for 20 min and then
(72) Francius, G.; Hemmerle, J.; Ball, V.; Lavalle, P.; Picart, C.; Voegel, J. C.;
Schaaf, P.; Senger, B. J. Phys. Chem. B 2007, 111, 8299–8306.
Embedded SilVer Ions-Containing Liposomes Langmuir, Vol. 24, No. 18, 2008 10211
cooled to room temperature. The fluorescence intensity of CF was
then measured with a VersaFluor fluorometer (BioRad) with an
excitation wavelength at 490 nm and the emission was measured at
520 nm. A calibration curve of CF in the medium used for the
destruction of the coating was then established. We assumed that
all vesicles prepared were aggregated with PLL before deposition
on the film, yielding the lipid content. The results are presented as
the average value of at least three independent experiments with
their standard deviation.
Release of Silver Ions from AgNO3 Coatings. The release of
silver ions from the AgNO3 coating was studied at room temperature
and at 37 °C by the determination of the silver ions present in the
supernatant of the coating. Gravimetrical analysis was performed
on AgNO3 coatings prepared on 30 mm spherical cover glasses with
1 mL of supernatant. To this aim, 0.8 mL of the liposome aggregates
(see paragraph above) were placed on 30 mm cover glasses previously
covered with (PLL/HA)20 film and dried under a hood. The dry
samples were hydrated with 1 mL of HEPES and stored at room
temperature or 37 °C. At defined time intervals, 200 µL aliquots
were withdrawn and mixed with the same volume of 10-3 M NaI.
After washing with water and centrifugation, the AgI precipitates
were placed on weighed 12 mm spherical microscopy cover glasses
and calcined at 300 °C until a constant weight. Then the amount of
AgNO3 released was calculated at each time interval. One hundred
percent of released AgNO3 corresponds to the total amount of silver
ions deposited on the glass slide followed by the drying and
rehydration procedure. To determine this value, the film was dissolved
by addition of 1 mL of Tris buffer solution (0.5 M Tris, 0.25 M
NaCl, pH 8.3) with 1% of Triton X100 followed by heating to 75
°C for 20 min. Then gravimetric analysis was done as described
above. Three samples were used to determine the standard deviation.
Minimal Inhibitory Concentration (MIC) Determination of
AgNO3 in Solution. Gram-negative bacteria, E. coli strain CIP 53
126, were used as a model system and were cultivated on tryptic
soy agar (TSA) medium and incubated at 37 °C. The cell suspension
was diluted with HEPES buffer/Muller Hinton broth (Biokar
Diagnostics, BK108HA) (10:2 v/v) to obtain a final bacteria
concentration in the range of (1-3) × 106 colony-forming units
(cfu)/mL. The minimal inhibitory concentration (MIC) is defined as
the lowest concentration of an antimicrobial drug that inhibits the
visible growth of a microorganism after overnight incubation. One
milliliter of the prepared bacterial suspension was mixed with the
same volume of AgNO3 solution at different concentrations prepared
by consecutive dilutions by a factor 2 starting from a concentration
of 10-2 M. All tubes were incubated at 37 °C for 20 h. The last tube
remaining transparent in the determined range is defined as the MIC.
Antibacterial Activity Test of AgNO3 in Solution and AgNO3
Coatings. The antibacterial activity of AgNO3 in solution and in
AgNO3 coatings were determined by following the evolution of the
number of viable E. coli cells with time. E. coli cell suspension was
prepared as described above with a final concentration of bacteria
in the range (1-3) × 106 cfu/mL. One milliliter of this bacterial
suspension was placed in 24-well culture plates containing either
AgNO3 solution at a given concentration or a glass covered by the
AgNO3 coating with the desired content in silver ions. These plates
were incubated at 37 °C and rotated at 100 rpm (Aerotron INFORS
AGCH-4103). At defined time intervals, the aliquots (50 µL) of the
cells were withdrawn and consecutively diluted (10×) with Muller
Hinton broth. Viable bacteria were determined by plating 100 µL
of each dilution on TSA medium and counting the developed colonies
after incubation at 37 °C during 20 h. All experiments were done
in triplicate and are presented with standard deviation.
Results and Discussion
Bactericidal Property of AgNO3 in Solution. As a first step,
the MIC of AgNO3 in solution was determined for E. coli. In
our case, MIC is equal to 22 µg/mL (1.3 × 10-4 mol/L). The
MIC of AgNO3 was reported as 2.3573 or 3.9 µg/mL74 for E. coli
cells cultivated in Luria-Bertani broth. The MIC of silver ions
is typically found in the range of 5-40 µg/mL,75 depending on
the local environment, i.e. the growth media. The use of Muller
Hinton broth could explain the 10-fold increase of the MIC of
AgNO3 compared to the value found for Luria-Bertani broth.
In a second step, the kinetics of bacteria growth in AgNO3
solutions at various concentrations was studied (Figure 1). For
incubation times up to 2 h, a strong decrease of the viable E. coli
cells is always observed for the whole range of explored silver
ion concentration from 6 to 450 MIC. At 300 and 450 MIC of
AgNO3 in solution, a 5-log reduction of the bacteria number was
found respectively for an incubation time of 75 and 15 min. For
the more concentrated AgNO3 solution, i.e. 450 MIC, the
antibacterial effect of silver ions becomes very efficient in terms
of time of contact between bacteria and silver ions.
Liposomes Characterization. The first step to build a
liposome-based biocoating is to determine the right lipid
composition of the vesicles. Liposomes were prepared with a
phase transition temperature close to 37 °C since this temperature
corresponds to the optimal temperature for growth of many
bacteria. This is also physiological temperature. DPPC/DPPG/
CL vesicles (80/10/10 w/w) characterized in a previous study63
were compared to DPPC/DMPC/DPPG/CL vesicles (60/20/10/
10 w/w). DPPG provides a negative charge for the vesicles,
enabling their complexation with polycations (PLL) by means
of electrostatic interactions, and CL provides rigidity to the
vesicles. DPPC/DPPG/CL vesicles do not release their cargo for
a long time (up to 1 week or more) if the temperature is kept
below the transition temperature, determined to be 41 °C.
Addition of a lipid having a lower transition temperature than
this former composition should decrease the transition temperature
of the final mixture. DMPC is a perfect candidate, as it is a
saturated lipid like DPPC with a shorter carbon chain and it has
a transition temperature of 23 °C. Taking into account that the
addition of a new lipid to the lipid mixture can decrease the
transition temperature proportionally to its content,76 the final
DPPC/DMPC/DPPG/CL ratio of 60/20/10/10 w/w should lead
to a transition temperature of about 37 °C. The respective transition
(73) Kong, H.; Jang, J. Langmuir 2008, 24, 2051–2056.
(74) Keleher, J.; Bashant, J.; Heldt, N.; Johnson, L.; Li, Y. Z. World J. Microbiol.
Biotechnol. 2002, 18, 133–139.
(75) Burrell, R. E. Ostomy Wound Manage. 2003, 49, 19–24.
(76) Taylor, K.; Craig, D. In Liposomes: A Practical Approach, 2nd ed.;
Torchilin, V., Weissig, V., Eds.; Oxford University Press: Boston, MA, 2003; pp
79-103..
Figure 1. Evolution of the number of viable E. coli cells versus time
in the presence of AgNO3 solutions. Bacteria were put into contact with
AgNO3 solutions at a concentration of (O) 6 MIC, (b) 150 MIC, (∆)
300 MIC, and (2) 450 MIC. The initial concentration of bacteria was
around 106 cfu/mL. The MIC of AgNO3 in solution was equal to 22
µg/mL.
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temperatures of the prepared DPPC/DPPG/CL and DPPC/DMPC/
DPPG/CL were determined by DLS measurements (Figure 2).
The method is based on the modification of the optical properties
of aqueous surfactant solutions upon phase transition in the
phospholipid bilayer membrane.62,77 The mean count rate (the
average number of detected photons per second), i.e. light
scattering of the vesicles, was found to change dramatically when
the transition temperature is reached. For DPPC/DPPG/CL
vesicles, the curve of mean count rate versus temperature
decreases when the temperature was set above 40 °C. This result
agrees with previous data where the transition temperature was
found to be close to 41 °C for such vesicles.78 DPPC/DMPC/
DPPG/CL vesicles differ from DPPC/DPPG/CL ones just by
substituting 20% of DPPC by DMPC. Due to this fact, we can
suppose that the DPPC/DMPC/DPPG/CL vesicles should behave
similarly, but with a reduced transition temperature that can be
detected correctly by DLS. The shape of the curve allows effective
determination of the phase transition temperature for these
vesicles. It lies around 34 °C and is close to the expected one
(37 °C).
Liposome Aggregation with PLL. In the present study, we
investigate the complexation of DPPC/DMPC/DPPG/CL vesicles
by the cationic polypeptide PLL. The complexation profile has
a cupola-like shape and shows clearly a strong liposome
aggregation over a wide range of PLL amino group/DPPG molar
ratio of 0.2-10 (Supporting Information, Figure S-1). When the
charge of the PLL coating is almost neutralized by the liposome
surface charge (i.e., the isoelectric point), the PLL-coated particles
have a strong tendency to form aggregates. The reason for
liposome aggregation may be a nonhomogeneous overcompen-
sation of the surface charge of the liposomes by the PLL
molecules. The DPPC/DMPC/DPPG/CL vesicle complexation
profile is wider than that of DPPC/DPPG/CL vesicles for the
same content of charged DPPG. Indeed, their aggregation has
been observed at a ratio of 0.4-1.5.62-64 The stronger aggregation
of DPPC/DMPC/DPPG/CL vesicles could be due to the smaller
size of the uncoated vesicles compared to uncoated DPPC/DPPG/
CL vesicles, respectively 83 ( 5 and 129 ( 2 nm. Bridge
aggregation has a significant effect on the aggregation of small
particles when the size of the bridging agent (in this case PLL)
is comparable to the size of the vesicles. DPPC/DMPC/DPPG/
CL vesicle aggregates at a molar PLL amino group/DPPG ratio
equal to 2 were selected for the preparation of AgNO3 coatings
[i.e., their deposition on (PLL/HA)20 polyelectrolyte films]
because they can contain large amounts of encapsulated silver
ions and are positively charged. Indeed, such aggregates have
a diameter of about 1 µm (Supporting Information, Figure S-1)
and a -potential of 32 ( 4 mV. The positive surface charges
could provide electrostatic bonding of the aggregates to the
negatively charged (PLL/HA)20 multilayers.
The stability of aggregates of vesicles is very important for
this study, since the vesicles should not release the cargo till the
release is needed. We have demonstrated in a previous study that
PLL-covered liposomes are able to keep not only the encapsulated
dyes, like carboxyfluorescein,63 but also small ions, like
ferrocyanide ions.60 In this last case, we demonstrated (by means
of cyclic voltametry) that the spontaneous release from the internal
lumen of the vesicles is pretty slow as it extends over more than
12 h. However, ferrocyanide ions should be considered as less
favorable ions for long-term encapsulation in vesicles.
We have also encapsulated calcium ions in vesicles and showed
that upon PLL coating no significant calcium release was found
after long-term storage. Indeed, at least part of these calcium
ions were used to induce the precipitation of calcium phosphates
inside of the vesicles which also contained an enzyme, alkaline
phosphatase. This triggered the production of phosphate anions
upon permeation of an amphiphilic phosphate-containing substrate
through the polyelectrolyte multilayer film as well as through
the lipid bilayer.79
The group of Kabanov has also demonstrated, using conduc-
tometry, that sodium chloride encapsulated in the vesicles is not
released from the internal lumen when poly(4-vinylpyridine) is
adsorbed on the surface of the vesicles.71 However, the adsorption
of quaternized poly(4-vinylpyridine) induced some ion leakage
from the vesicles, showing that the incorporation of aliphatic
chains from the polycation induces some disorder in the lipid
bilayer. PLL is devoid of hydrophobic side chains, and we
previously demonstrated that it does not change the main phase
transition temperature of DPPC/DPPG-containing vesicles.63 In
this study, we have shown that PLL adsorption does not induce
release of encapsulated silver ions from the internal lumen of the
vesicles upon aggregation. This was checked by mixing the
supernatant of aggregated vesicles with 0.15 M NaCl solution,
which did not induce any visible precipitation of AgCl, which
should be observed in the supernatant once aggregated vesicles
would release encapsulated AgNO3.
Fabrication of AgNO3 and CF Coatings. AgNO3-liposomes
were obtained by hydration of the thin lipid film with 4 mL of
AgNO3 solution of 1 M (170 mg/mL). After the formation of
AgNO3-liposome aggregates by addition of PLL, AgNO3
coatings were designed on a first step by deposition of
AgNO3-liposome aggregates diluted at a given concentration
on (PLL/HA)20 multilayers. After water evaporation at room
temperature, the deposited vesicles formed a thin micron-sized
coating and were maintained at the surface by adding HA/PLL/
HA capping layers (Scheme 1). Additional HA/PLL/HA layers
were deposited on the architecture by alternated immersion of
the glass slide in HA and PLL solutions separated by rinsing
steps. The amount of silver ions in the final coating was found
by film destruction followed by gravimetric analysis of silver
ions (see Experimental Section).
To evaluate the effect of (PLL/HA)20 matrix on the stability
of the liposome aggregates deposited on it, CF coatings were
realized using the same procedure as with Ag-liposome
(77) Michel, N.; Fabiano, A. S.; Polidori, A.; Jack, R.; Pucci, B. Chem. Phys.
Lipids 2006, 139, 11–19.
(78) Lipid Data Bank, www.lipidat.chemistry.ohio-state.edu.
(79) Michel, M.; Arntz, Y.; Fleith, G.; Toquant, J.; Haikel, Y.; Voegel, J.-C.;
Schaaf, P.; Ball, V. Langmuir 2006, 22, 2358–2364.
Figure 2. Mean count rate, measured by DLS, as a function of the
temperature for (b) DPPC/DMPC/DPPG/CL (60/20/10/10 w/w) and
(O) DPPC/DPPG/CL (80/10/10 w/w) liposomes. The phase transition
temperature, corresponding to the inflection point of the curves, is
indicated with vertical dashed lines.
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aggregates. After the dissolution of the coating, the fluorescence
intensity of the supernatant was measured to determine the CF
quantity embedded into CF coatings. It was found that 56( 12%
of the initially deposited CF remains in the film. This suggests
that part of the vesicles lost their integrity upon drying, probably
those located on the surface because of water evaporation.
However, a large fraction of the vesicles that are more deeply
embedded in the aggregates are stabilized by PLL and the
underlying hydrated PLL/HA film. This stabilization is confirmed
by the fact that when the CF-liposome aggregates are deposited
on a bare glass substrate, only 15 ( 4% of the initially deposited
CF-liposomes remains on the surface. The hydrogel-like PLL/
HA film plays the role of a spacer, which not only provides a
negatively charged surface for the attachment of positively
charged vesicles but also contains a quite high amount of water,
rendering the surface soft enough to bind the aggregates to the
surface. Moreover, in the scope of the design of a transient
bactericidal coating especially for implants, PLL/HA film
constitutes a very good candidate. It is known to be nonadhesive
for numerous cell types.80-82 This property could be very useful
to limit or inhibit cellular adhesion in addition to the bactericidal
effect of the coating.
The film loading capacity was also investigated. The loading
of the film was tuned by using CF-liposome aggregate
suspensions diluted at different concentrations, deposited on (PLL/
HA)20 multilayers, and capped by HA/PLL/HA layers. To evaluate
the film loading, CF coatings were dissolved, and the fluorescence
of CF in the supernatant was measured. Figure 3 represents the
fluorescence intensity of the supernatant after the dissolution of
the CF coating. CF encapsulated in the film increases linearly
with theconcentrationofdepositedsuspensionof theCF-liposome
aggregates.
Triggered Release of AgNO3. DPPC/DMPC/DPPG/CL
liposomes were chosen to build AgNO3-liposome aggregates
because of their phase transition temperature close to 37 °C,
optimal for the growth of numerous bacteria. Upon crossing the
transition temperature due to the increased lipid mobility, the
permeabilization of either single liposome or liposome aggregates is dramatically increased. The PLL coating does not induce any
changes in the behavior of “solid” liposomes; however, it increases
the permeability of “fluid” liposomes.63 The release of silver
ions entrapped in AgNO3 coatings was studied by gravimetry
analysis of the supernatant (Figure 4). At defined time intervals,
aliquots were withdrawn from the supernatant and mixed with
a NaI solution to form AgI precipitates. The precipitates are then
(80) Richert, L.; Schneider, A.; Vautier, D.; Vodouhe, C.; Jessel, N.; Payan,
E.; Schaaf, P.; Voegel, J.-C.; Picart, C. Cell Biochem. Biophys. 2006, 44, 273–
285.
(81) Richert, L.; Boulmedais, F.; Lavalle, P.; Mutterer, J.; Ferreux, E.; Decher,
G.; Schaaf, P.; Voegel, J.-C.; Picart, C. Biomacromolecules 2004, 5, 284–294.
(82) Mhamdi, L.; Picart, C.; Lagneau, C.; Othmane, A.; Grosgogeat, B.;
Jaffrezic-Renault, N.; Ponsonnet, L. Mater. Sci. Eng. C 2006, 26, 273–281.
Scheme 1. Design of AgNO3 Coatingsa
a (af b) Liposomes complexation with PLL resulted in the formation of AgNO3-liposome aggregates. (bf c) Deposition of AgNO3-liposome aggregates
on (PLL/HA)20 film followed by additional coating with HA/PLL/HA layers.
Figure 3. CF encapsulated in CF coatings versus the lipid content
deposited on the film. CF fluorescence was measured in the supernatant
after the decomposition of CF coating, and the lipid content is assumed
to be equal to the amount adsorbed. The dotted line is a linear fit going
through zero. The error bars correspond to the standard deviation of
three different samples.
Figure 4. Release of silver ions from AgNO3 coating versus time at (b)
room temperature and (O) 37 °C. Silver ions content in the supernatant
was determined by gravimetrical analysis.
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weighted and calcinated till a constant weight to determine the
Ag+ amount released by the AgNO3 coating. No silver ions were
detected in the supernatant up to 3 h at room temperature. When
the AgNO3 coating is stored at 37 °C, the situation becomes
strongly different. After 30 min of incubation, 11 ( 6% of the
silver ions encapsulated in the coating is released. More than 54
( 17% of the entrapped AgNO3 is released within 90 min,
indicating a continuous release of ions. At 37 °C, the AgNO3
coating loses about 100% of its content within 15 h. This quite
fast release of Ag+ ions could have a very efficient antibacterial
property. However, this could also be a weak point of the coating
concerning its lifetime. A slower release of Ag+ ions could give
a longer lifetime but a weaker efficiency against bacteria. In the
present study, we were interested in validating the use of this
coating as an antimicrobial treatment of surfaces. Future studies
will deal with tuning the release of silver ions.
The storage of AgNO3 coating was also followed. The coating
is quite stable upon storage up to 1 day; however, long-term storage
leads to a partial leaking of the active compound. Indeed, after 5
days at 4 °C, the coating keeps still 32% of the initially entrapped
AgNO3. This loss of material could be due to a spontaneous release
of AgNO3 or erosion of AgNO3-liposome aggregates. The vesicle
aggregates used in this study (about 1 µm in diameter) have an
excess of charge and a strain in the structure that can destabilize the
lipid membrane domains, increasing the membrane permeability.
Antibacterial Activity of AgNO3 Coating. The antibacterial
activity of AgNO3 coatings was tested against E. coli with different
content inAgNO3.Asacontrol, (PLL/HA)20 filmspreviouslydipped
in 0.1 M AgNO3 were put into contact with an E. coli bacterial
suspension. Such films had no antibacterial activity. Moreover, PLL/
HA films prepared with liposome aggregates without AgNO3 have
also no antibacterial activity.
Figure 5 presents the concentration of viable E. coli cells in
contact for 20 h with various AgNO3 coatings. A very small
effect is found up to 11 ng/cm2. Then, the viability decreases
strongly with complete bacteria death for concentrations above
42 ng/cm2. For AgNO3 coatings with 21 ng/cm2 AgNO3, a 5-log
reduction of the bacteria number is observed compared to a coating
with no AgNO3 encapsulated. Liposomes represent perfect
containers for small solutes due to (i) their low lipid membrane
permeability, (ii) a possible temperature control of their perme-
ability, and (iii) the possibility to embed a large amount of active
compounds in a controlled manner. In a further step, the decrease
of viable bacteria with time was followed in contact with a highly
charged coating of 120 ng/cm2 during the time.
Kinetics of Bacteria Growth in the Presence of AgNO3
Coating: Typical Decay Kinetics. The decay kinetics with a 120
ng/cm2 AgNO3 coating was monitored over about 2.5 h (Figure 6).
After 2 h of incubation, a 4-log reduction of the number of viable
bacteria was observed. A nearly complete bacteria death is
observed after 2.5 h of contact with the AgNO3 coating. The
progressive release of AgNO3 through the liposome walls induces
a high local concentration on the surface of the coating in the
neighborhood of bacteria. Ag+ ions react with the cell membranes
of bacteria and disrupt crucial metabolic proteins and enzymes,
leading to cell death.
The present strategy is also to be compared with multilayers
prepared with embedded silver nanoparticles in the poly(acrylic
acid)/quaternized poly(ethylene imine) system.45 The antimi-
crobial polyelectrolyte multilayers, obtained by in situ wet phase
reduction of Ag+ ions into silver nanoparticle, can release silver
ions into the surroundings as was shown by the Kirby-Bauer
test. These coatings show an about 2-log reduction of the number
of viable E. coli cells after 2 h. Thus the AgNO3-liposome
aggregate based system has a fast and strong performance against
bacteria growth compared to other multilayer coatings.
Conclusions
Liposome aggregates filled with AgNO3 solution leading to
AgNO3 coating were prepared with a temperature control of
silver ions in the supernatant. The AgNO3 coatings can be
embedded in PLL/HA films. The architecture showed a strong
and rapid antibacterial effect against E. coli. A contact of 120
min with an AgNO3 coating (with 120 ng/cm2 AgNO3 concen-
tration) induces a 4-log reduction of the bacterial population.
PLL/HA films could not be directly loaded with noticeable
amounts of silver ions to induce bacterial death. The AgNO3
coating represents a solvent-based antibacterial system through
release of bactericidal agent from the film under external stimuli.
In the next coming steps, we foresee performing experiments
aimed to prepare silver ions containing coatings with increased
stability and with control of release over a longer period of time.
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Figure 5. Number of viable E. coli cells after an incubation of 20 h at
37 °C versus AgNO3 concentration encapsulated into AgNO3 coating.
The initial concentration of bacteria put into contact with AgNO3 coatings
was around 106 cfu/mL. The AgNO3 content is expressed as the amount
of AgNO3 encapsulated per cm2.
Figure 6. Evolution of the number of viable E. coli cells as a function of
the incubation time in contact with AgNO3 coating (120 ng/cm2 in AgNO3).
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